The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection

157 Pages·1995·1.59 MB·English

The Effectiveness of Drug Abuse Treatment:
Implications for Controlling AIDS/HIV
Infection
September 1990
OTA-BP-H-73
NTIS order # PB91-104885
The Effectiveness of Drug Abuse Treatment:
Implications for Controlling AIDS/HIV Infection
Jane E. Sisk, Project Director
Evridiki J. Hatziandreu, Study Director
Rita Hughes, Research Assistant
Other Contributing Staff
Sharon Hamilton, Research Assistant
Virginia (Cwalina, Office Administrator
Eileen Murphy, P.C. Specialist
Carolyn Martin, Word Processor Specialist
Angela Dantzler, Secretary
September 1990
A Background Paper in OTA’s
Series on AIDS-Related Issues
The views expressed in this Background Paper do not necessarily
represent those of the Technology Assessment Board, the Technology
Assessment Advisory Council or their individual members.
This paper was prepared for desk-top publishing by Carolyn Martin and Eileen Murphy.
The impact of AIDS and other disease associated with the human
immunodeficiency virus (HIV) on the Nation’s health and health care resources is
continuing. Congress has responded to the AIDS crisis with large increases in
Federal funds for basic and applied research and education and has begun to
grapple with the difficult issues involved in financing AIDS-related health care.
AIDS is on the agenda of a large number of congressional committees and raises
numerous important issues that require congressional attention and decisions.
These developments led to a recommendation, in May 1987, by OTA’s Technology
Assessment Board, with encouragement from the Legislative Subcommittee of the
House Appropriations Committee, that OTA provide assistance on AIDS-related
issues to Congress on a sustained basis. That request led to OTA’s series of
studies on AIDS-related issues. This Background Paper is the sixth in that series.
In 1989, the Board extended the OTA project on AIDS for another 2 years.
This Background Paper examines the evidence of the effectiveness of drug
abuse treatment; it also evaluates the role that such treatment might play in
reducing the spread of HIV. Because most intravenous drug users are not in
treatment, the paper also examines other approaches to HIV prevention among
this high-risk group.
The preceding papers in this series were Do Insects Transmit AIDS? (Sep-
tember 1987); AIDS and Health Insurance - An OTA Survey (February 1988); How
Effective Is AIDS Education (June 1988); The Impact of AIDS on the Kaiser
Permanence Medical Care Program (Northern California Region) (July 1988); and
How Has Federal Research on AIDS/HIV Disease Contributed to Other Fields?
(April 1990) (see inside back cover for information on how to order these publica-
tions). Previous OTA reports addressing AIDS-related issues include: 1) Blood
Policy and Technology (January 1985), 2) Review of the Public Health Service’s
Response to AIDS (Technical Memorandum, February 1985),3) The Costs of AIDS
and Other HIV Infections: Review of the Estimates (Staff Paper, May 1987), and 4)
Medical Testing and Health Insurance (August 1988).
~zf
A J $ L a ?-
2
OHN H. GIBBONS
~Director
CONTENTS
Chapter Page
1. Introduction and Summary....* .*...*.. *e*** ****. *.*... ***** ***. **.** *****e**.********.************. .**.. **** .**************-1
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .*. . . . . . . . . . 1
l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . l. .. . . . . . . . . . . . . . . . . . . . . . . . . . l. . * . . . . . . . . . .l . . . . . . . . . •, .................
Summary of the Findings. .*. . . . . . . . . . . . . . . . . . . . . *.... *. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .* . . . . . ..**. . . . . . . . . . . . . . . . .* , . . . .2
l l l l l
Magnitude of the Problem . . . . . . . . . . . . . . . . . . . . . . . ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
l l l l l l l l l l l l l l l l l
Assessing the Effectiveness of Drug Abuse Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2
l l l l l l l
Implications of the Findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .**. *... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .*. ..*** . . . . . . . . . . ** . . . . . . . . . . . . .* . . . .8
l l l l l l
Reaching People Not in Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .* . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
l l l l l l
Improvement in Quality. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
l l l l l l l l l l l
Future Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..... 10
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............... ........1...0.
l
2. Drug Use and HIV Infection: The Current Situation. . . . . . . . . . . 13
l .000..0..00 .0.0000 .0......0...0.. . . . . . . . . . . . . . . . l 0.....0.. l O..*..**. l ..*.*******. l
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .............. .....1...3......
Use of Illegal Drugs in the United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Substance Dependence, Substance Abuse, and Casual Use. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Drugs of Abuse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........ 13
Magnitude of the Drug Abuse Problem. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Drug Use and HIV Infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Routes of Transmission That Link Drug Use to AIDS, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29
l
Estimates of IV Drug Use. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Estimates of Risk Behaviors Among Drug Abusers. . . . . . . . . . . . . . . . . . . . ... , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
HIV Seroprevalence Among Drug Users. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
l
AIDS Cases Reported to the Centers for Disease Control. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .34
l
Cost Estimates of Drug Abuse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .* . . .38
l
Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .............. .........3....9......
3. Treatment for Drug Abuse in the United States . . . . . . . . . . . . . ***.. ***.*..** .*.** *.*.....* ***** *.***...* . . . . . . . . . . . . . . . . .*..*.**.***** .**** **..**.41
l l l l l
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........... ........4....1......
Treatment Modalities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........... 41
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............ 41
Role of Detoxification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Pharmacotherapy Treatment Approaches. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Drug-Free Treatment Approaches. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
The Role of Multimodality Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Treatment Programs in the United States. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............. 49
NDATUS: Description and Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
SADAP: Description and Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
The Extent of HIV Testing and Counseling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
Shortages of Treatment Slots. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Information on the Cost of Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Summary of the Findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .... 58
CONTENTS-Continued
4. The Effectiveness of Treatment for Drug Abuse ***.*********..****************** ***..*.************.**..*****.* ***** *****0 ..*..* ***** *****w**e**59
l l l
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
. . . . . . . . . . ............. ..........**.*..
Natural History of Drug Abuse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . **.............*.***** . . . . . . . . . . . . . . . . . . . . . . 5. 9
. . . . . .
Overview of Drug Abuse Careers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
... ... *o.. *.*o.. O***..* . . . . . . . . . .
Heroin Abuse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .*..... *+*** . . . . . . . . . . . . . . . . . . . . . 60
Cocaine Abuse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
. . . . . . . . . . . . . . . . . . . . . . . . . . ... **. ****.............. ** . . . . .
Methodologies.1 Problems in the Evaluation of Treatment Effectiveness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .61
Study Design. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............. 62
Definition of Treatment and Outcome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
l
Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...........6....4 ....
DARP and TOPS: A Description of the Two National Multimodality Studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .65
Drug Abuse Reporting Program (DARP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Treatment Outcome Prospective Study (TOPS). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........ *.. ****. *...... .*.. **.**6*5
Treatment Effectiveness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........66
Methadone Maintenance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Other Pharmacological Agents. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
Therapeutic Communities (TCs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ’79
Outpatient Drug Free (ODF) Programs. . . . . . . . . . . . . . . . . . . . . . 84
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .*, .. ** . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Results Combining Treatment Modalities. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Acupuncture. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............. 88
Parameters Related to Treatment Outcome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Matching. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............8... 9.*..
Other Contemporary Issues Related to Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .90
Future Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... .** 96
Summary and Policy Implications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5. Treatment for Drug Abuse as a Strategy to Prevent HIV Infection. . . . . . . . . . . . . . . . . . . . . . . . . . . ****e O**o*o*.e*o*o** *. ”**e..eoee*o . . . . .101
l
Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .............. .......1...*0*1*
Methodological Problems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. 02
l **. .*.......
Study Design Issues. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Study Outcome Issues. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .102
l
Measurement Issues. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... **.* 103
Validity of the Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Effectiveness of Drug Abuse Treatment to Prevent HIV Infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Reduction in Drug Use and Risk Behaviors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . * O . . . . . . . . . . .104
l
HIV Infection and Entry Into Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .*.. 105
Medical Maintenance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Interim Methadone Maintenance Program. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Additional Approaches to Prevent HIV Infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
The Importance of Preventing IV Initiation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Risk Reduction Through Needle-Exchange Programs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Sale and Possession of Injection Equipment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...*.,..*.1*..11
The Role of Outreach Programs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Summary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .................... ..1...1....3..
CONTENTS--Continued
Appendix
A. Method of the Study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .......... .... 115
l l
B. Workshop Participants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . *. *...*.... . . . . . . . . . . . . .*. . . . . . . . . . . . . . . . . . . . . . . . . ....0,.,., . . . . . . . . . . . . . . . . . . . . . . ,, .,....0.. . . . . . . . . . . . ,.1*.1 *6
C. Acknowledgements. . . .** . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . , , . . . . . . . . . . . . . . . . . . , , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
l l. . . . . . . . . . . .*. . . . . . . . l ** . . . . . . . . . l . . . . . l . . . . . . . . .
D. Glossary of Abbreviations and Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
l l l l l l l l l l l
E. Psychoactive Drugs Other Than Narcotics and Stimulants . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . .* . . . . . . . . . .* , . . . . . . . . . . . . . . . . . . . . . .122
l l l l l l l
F. Cost Benefit Analysis of Drug Abuse Treatment: Declines in Criminal Activity. . . . . . . . . . . . . . . . . . . . . . 125
. . . . . . . . . . . . . . . . . . .
G. Highlights From the 1989 National Drug and Alcoholism Treatment Unit Survey (NDATUS) ................127
References. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................ ................*.*..1.. 2...,8,
Boxes
Box Page
2-A. American Psychiatric Association’s Diagnostic Criteria for Psychoactive Substance Dependence ..........14
2-B. Other Information Systems on Drug Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
l
5-A. Drugs of Abuse and the Immune System. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Figures
Figure Page
2-1. Use of Any Illicit Drug During the Past Year, National Household Survey, 1985 and 1988......................fi
2-2. Any Illicit Drug Use by High School Seniors, 1975 to 1989. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2-3. Percent of Population Reporting Heroin Use in Lifetime by Region and Age Group, 1985 and 1988....23
2-4. Percent of Population Reporting Heroin Use in Lifetime by Sex and Race/Ethnicity, 1985 and 1988....23
2-5. Drugs Mentioned Most Frequently in Emergency Rooms Episodes, by Percent of Total Episodes........24
2-6. Trends in Cocaine and Heroin Emergency Room (ER) Mentions 1984 to 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25
l
2-7. Percent of Population Reporting Cocaine Use in the Past Month by Sex and Race/Ethnicity,
1985 and 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................ 2...5...*.
2-8. Cocaine Users During Past Year, 1985 and 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
. . . . . . . . . . . . . . . . . . . . . . . . .
2-9, Cocaine Use by High School Seniors, 1975 to 1989. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
. . . . . . . . . . . . . . . . . . . .
2-1o. Cocaine Trends in Past Year Among High School Seniors, 1975 to 1989. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28
2-11. Emergency Room Mentions of Cocaine and Heroin by Route of Administration, 1988. . . . . . . . . . . . . . . . . . . . . . . . . . .32
2-12. AIDS Cases in Adults and Adolescents by Risk Factor, June 1989 through May 1990 .... **... *.... *.*.. *.... ..,.34
l l
2-13. Reported AIDS Cases Associated With IV’ Drug Use per 100,000 Population United States, 1988........36
3-1. Drug Abuse Clients in Treatment by Setting and Modality According to the National Drug
and Alcoholism Treatment Unit Survey (NDATUS), Oct. 30, 1987. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51
3-2. Admissions of Drug Abuse Clients by Setting and Modality According to the State Alcohol
and Drug Abuse Profile (SADAP), Fiscal Year 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... .***..... ..**5....5
CONTENTS--Continued
Tables
Table Page
1-1. Percent of Self-Reported Outcomes by Clients in Methadone Maintenance
Treatment, Selected Studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1-2. Percent Self-Reported Outcomes by Clients in Therapeutic Communities, Selected Studies ...................6
1-3. Percent Self-Reported Outcomes by Clients in Outpatient Drug-Free Programs, Selected Studies ........7
2-1. Trends in Hospital Emergency Room (ER) Mentions of Cocaine Reported to the Drug
Abuse Warning Network (DAWN), by Metropolitan Area, 1984 to 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2-2. Percent Self-Reported Drug Injection and Needle-Sharing in Male Arrestees, Selected
U.S. Cities, January to March 1989. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2-3. Number and Rate Per 100,000 Population of AIDS Cases Associated With IV-Drug Use,
by Census Region and Race/Ethnicity, 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2-4. Projected Number of AIDS Cases, Persons Living With AIDS, and Deaths Attributable to AIDS
After Adjustment for Underreporting, 1989 to 1993. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
2-5. Projected Number of AIDS Cases by Risk Group, 1989 to 1993. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3-1. Drug Development Program of the National Institute on Drug Abuse (NIDA), 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . .44
3-2. Information on Drug Abuse Treatment Units, from the National Drug and Alcoholism
Treatment Unit Survey (NDATUS),, Oct. 30, 1987. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , 51
3-3. Number of Alcohol or Drug Treatment Units by State Alcohol or Drug Agencies According
to the State Alcohol and Drug Abuse Profile Data (SADAP), Fiscal Year 1988. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .53
3-4. Estimated Admissions of IV Drug Abusers and Total IV Drug Abusers, by State, Fiscal Year 1988....54
3-5. Drug Treatment Centers Providing Human Immunodeficiency Virus (HIV) Counseling, Testing,
and Partner Notification in Selected State and New York City, 1990 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3-6. Estimates of Waiting Lists for Alcohol and Other Drug Abuse Treatment, Sept. 29, 1989 .....................57
4-1. Percent Self-Reported Heroin Use and Crime by Males by Time in Methadone Maintenance
Treatment, 1985. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........6....8.....
4-2. Percent Self-Reported Opiate Use, Criminal Activity, and Employment by Males
in a Methadone Maintenance Treatment, DARP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4-3. Percent Self-Reported Drug Use, Criminal Activity, and Employment by Methadone
Maintenance Clients Treated at Least 3 Months, TOPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4-4. Odds Ratio for Post-Treatment Outcomes in the First Year after Methadone Maintenance
Treatment, by Treatment Duration, TOPS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4-5. Percent Success Among Program Graduates, Phoenix House. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ., .4$.0 79
4-6. Percent Success Among Program Dropouts, Phoenix House. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
.
4-7. Percent Self-Reported Opiate Use, Criminal Activity, and Employment by Males
in Therapeutic Communities, DARP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4-8. Percent Self-Reported Drug Use, Criminal Activity, and Employment by Therapeutic
Community Clients Treated at Least 3 Months, TOPS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4-9. Odds Ratio for Post-Treatment Outcomes in the First Year After Residential Treatment,
by Treatment Duration, TOPS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4-1o. Percent Self-Reported Opiate Use, Criminal Activity, and Employment by Males
in Outpatient Drug-Free Treatment, DARP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4-11. Percent Self-Reported Drug Use, Criminal Activity, and Employment by Outpatient Drug-Free
Clients Treated at Least 3 Months, TOPS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4-12. Odds Ratios for Post-Treatment Outcomes in the First Year After Outpatient Drug-Free
Treatment, by Treatment Duration, TOPS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Chapter 1
Introduction and Summary
INTRODUCTION physical problems or despite recurrent use in physi-
cally hazardous situations. Casual users, the least
Two health epidemics in the United States have
serious category, take certain drugs only occasionally
overlapped with disastrous results: drug abuse, a
or in low or moderate doses, usually in social con-
chronic relapsing disorder, and human immuno-
texts, and do not exhibit the maladaptive behavior
deficiency virus (HIV) infection, the cause of AIDS.
patterns associated with substance dependence and
Because these epidemics have affected a wide range
substance abuse. Casual use still poses risks to the
of areas from medical care to law enforcement, the
individual and society since any needle-sharing or
cost to society is substantial, both in tangible and
drug-associated high-risk sexual behaviors may
intangible terms. A fatal link between the two
transmit HIV and other infections.
epidemics compounds the problem, as the multi-
plicity of HIV transmission modes makes drug users,
In this Background Paper, the terms drug abuse
intravenous (IV) drug users in particular, a critical
and drug dependence are used interchangeably, and
group in the spread of HIV infection.
the term drug abuser also includes drug addicts, who
have lost control over their substance use.
Three modes of transmission connect drug abuse
. and HIV infection. One occurs among IV users of
drugs, primarily heroin and cocaine, who share Drug abuse is a chronic relapsing disorder; its
injection equipment that is contaminated with pattern of relapses and remissions resembles other
infected blood. Through sexual transmission, the chronic diseases, such as arthritis and chronic
second mode, infected IV drug users may pass HIV depression. Similarly, no treatment exists to totally
to their sexual partners. In particular, crack, a smok- eradicate the condition. Unlike treatment for acute
able and powerful form of cocaine, is associated with conditions, such as a broken leg or a simple infection,
sexual behaviors at high risk of HIV transmission. treatment for drug abuse shares the same objectives
The third mode of transmission occurs during preg- as treatment for other chronic conditions: 1)
nancy or shortly after birth, when women infected amelioration of symptoms (e.g., impaired function-
through IV drug use or by IV drug-using sexual ing) and 2) prolongation for as long as possible of
partners may transmit the virus to their infants. symptom-free intervals (e.g., maintenance of the
desired behavior changes).
The use of psychoactive substances ranges from
casual and recreational use to abuse and dependence Preventing the spread of HIV among drug
or addiction. Although all degrees of drug use, if abusers is a formidable task. That drug abuse is a
associated with certain behaviors, put users at risk of chronic relapsing condition and that drug abusers are
HIV infection, more frequent high-risk behaviors, of a heterogeneous population with other social and
course, increase the likelihood of viral transmission. behavioral problems pose obstacles to effective
Substance dependence, the most severe condition, is treatment. Moreover, the increasing use of
characterized by compulsive use and loss of control injectable and smokable cocaine, coupled with the
over drug use (6). Continued use despite adverse lack of an effective medication to treat cocaine
consequences, failed attempts to stop, considerable abuse, makes even more difficult the control of HIV.
time spent procuring the drug, and symptoms of Sexual behavior appears more difficult to modify
tolerance and withdrawal are characteristic of sub- than needle-sharing behavior. This fact further
stance dependence. A substance abuser continues underscores the diligence required to halt this
use despite social, occupational, psychological , or tremendous public health challenge (341).
-1-
2- The Electiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection
This OTA Background Paper has a dual role: it cocaine and heroin users; and 25,000 IV users of
examines evidence for the effectiveness of treatment other drugs (282). Given estimation problems and
for drug abuse and evaluates the role of drug abuse the passage of time, however, the actual number of
treatment as a strategy to prevent HIV spread. IV drug users may differ substantially (282).
Because most IV drug users are not in treatment, the
study also examines other approaches to HIV pre- Of all IV drug users, 80 to 90 percent are not in
vention among this high-risk group.l treatment at any given time (216a,332a,341). Among
users not in treatment who volunteered to participate
The remainder of this chapter summarizes the in U.S. urban outreach programs from 1987 to 1989,
main findings. Chapter 2 reviews the current 34 percent injected predominantly heroin, 31 percent
situation regarding drug use and HIV infection in the cocaine, 33 percent combinations of heroine and
United States. Chapter 3 provides background cocaine, and 2 percent amphetamines or other drugs
information about the drugs of abuse and various (340). Heroin was the predominant drug for almost
treatment modalities. Chapters 4 and 5, respectively, 60 percent who reported daily drug injection. Most
review the existing literature on the effectiveness of of these volunteers, 60 percent, had previously been
drug abuse treatment and on its role in preventing in treatment. Substantial proportions engaged in
HIV infection. The various appendixes describe the behaviors that put them at high risk of contracting or
method of the study; acknowledge experts in the field transmitting HIV: 78 percent reported sharing drug
“who provided valuable advice; describe drugs of injection equipment with another IV drug user; 20
abuse other than opiates and cocaine; summarize a percent shared equipment with strangers; and 48 to
cost-benefit analysis of drug abuse treatment; and 85 percent, depending on the type of sexual activity,
review highlights from the most recent National never used a condom (340).
Drug and Alcoholism Treatment Unit Survey.
Of approximately 350,000 drug clients in
SUMMARY OF THE FINDINGS
treatment in fall 1989, about 41 percent had used
drugs intravenously (332a). Public and private facil-
Magnitude of the Problem
ities across the country reported treating almost 1
HIV is transmitted through sharing contaminated million drug users of all kinds during the year ending
needles and other equipment used to inject drugs. with September 1989.
The sharing of injection equipment is a common
practice throughout the United States in areas of The association between drug use and HIV
high and areas of low HIV seroprevalence, with infection is not confined to IV drug use. Sexual
reported rates of sharing among IV drug users as behaviors associated with the crack epidemic, such as
high as 70 to 100 percent (8). Heroin and cocaine sex for drugs, casual sex with multiple partners, and
alone or in combination are the most common careless sex while high on drugs, put drug users at
injectable drugs, while amphetamines are popular in increased risk of HIV infection (112). In 1988, about
certain parts of the country. Overall, the estimated 1 million people in the United States had used crack
number of IV drug users in the United States ranges in the past year, and about 0.5 million had smoked it
from 1.1 to 1.8 million (64,220,307). Using data in the past month (330). Among 1988 high school
through 1985, the National Institute on Drug Abuse seniors, about 3 percent reported having smoked
(NIDA) estimated that there are 500,000 IV heroin crack during the previous year (320a).
addicts; 250,000 IV heroin users who are not addicts;
475,000 IV cocaine users; 150,000 overlapping IV Counting drug users and their sexual partners, an
estimated 1.8 million people are at risk of contracting
HIV (318). Currently, IV drug use is the second
most common risk behavior reported for AIDS cases
1
This paper does not examine issues related to drug abuse and in the United States, surpassed only by unsafe sex
HIV infection among adolescents. These issues are addressed in
an upcoming OTA Report on adolescent health expected to be among homosexual or bisexual men. In several
published in early 1991. Northeastern States and Puerto Rico, the number of
Chapter 1--Introduction and Summary 3
adult AIDS eases among IV drug users exceeds those into the category of programs that on philosophical
among homosexual men (335). Among women with grounds do not employ medications.
AIDS through May 1990, about 70 percent were
associated with IV drug use or an IV drug-using Evaluations of the effectiveness of treatment
sexual partner (349). Moreover, about 70 percent of assess whether a particular treatment approach has
the children with AIDS who were presumably reduced behaviors associated with drug abuse, chiefly
infected through perinatal transmission had mothers the frequent use of heroin or cocaine. Certain meth-
who were IV drug users or sexual partners of IV odological problems handicap interpretation of the
drug users. results. Almost all evaluations have studied groups
of people entering treatment programs and com-
African-Americans and Hispanics constitute 20 pared their behaviors before and after treatment.
percent of the U.S. population, but 44 percent of Recovery from drug abuse, however, may be influ-
AIDS eases through May 1990 (304a,349). In AIDS enced by many factors, such as previous treatment
associated with drug use, these groups have also been episodes, involvement with the criminal justice
disproportionately affected; they have accounted for system, pressure from family and friends, and reli-
79 percent of AIDS among IV drug users, 77 percent gious involvement. These factors may interact or
of AIDS among heterosexual partners of IV drug operate independently.
users, and 85 percent of children presumably infected
through mothers who were IV drug users or sexual Without randomly assigning people to treatment
partners of IV drug users (349). and having a control group for comparison, one
cannot separate the effect of treatment from the
Because of AIDS’ long gestation period, current effect of other factors that might affect behavior,
AIDS cases reflect drug use patterns and high-risk such as the individual circumstances of the people
behaviors that occurred 5 or more years ago. The who choose treatment (see ch. 4). Interpretation is
impact of more recent trends of heavy cocaine and rendered more difficult by the lack of information
crack use, which are associated with high-risk about the history of drug abuse careers. Although
behaviors for transmitting HIV, is yet to come. some people reduce or eliminate drug use without
treatment, not enough is known about the natural
Although declining trends in casual use of illicit history of this chronic, relapsing condition to
drugs have been reported from national surveys, estimate how many would improve regardless of the
these figures may underestimate the magnitude of intervention. In addition, the results generally
the problem. The major surveys exclude certain pop- consist of behaviors reported by the drug abusers
ulation groups that have a higher likelihood of drug studied, reports that may be biased. On average,
abuse, such as homeless people and those in prisons however, these self-reports have been found to
and jails (304,330). In addition, the magnitude of conform to other sources of information (149,267).
underreporting may have increased in recent years,
as social tolerance toward illicit drug use has Although research on drug abuse has intensified,
decreased (304). no completed studies have evaluated treatment for
crack. Nor are evaluations of more recent variations
Assessing the Effectiveness in traditional approaches, such as shorter residential
of Drug Abuse Treatment programs and self-help groups, yet available.
This Background Paper focuses on the three
Methadone Maintenance
treatment approaches that have been subjected to
the most evaluation: outpatient methadone Efficacy and Effectiveness--Methadone is a
maintenance programs, residential therapeutic com- synthetic narcotic used to treat dependence on
munities (TCs), and outpatient drug-free (ODF) opiates. Heroin, the most frequently abused opiate,
programs. Although other medications besides is administered mainly by injection. When
methadone are being developed and evaluated, none administered regularly in adequate doses, methadone
is in widespread use. Traditional TCs and ODFs fall can reduce the craving for heroin, prevent the onset “